Macro Group Pharmaceutical S.a.e. · EGX:MCRO
Macro Group Pharmaceutical S.a.e — Q1 2025 Earnings Presentation
15 slides from Macro Group Pharmaceutical S.a.e's earnings presentation, April 2025
Slide 1: Investor Relations Presentation 1Q 2025
Investor Relations Presentation 1Q 2025
Slide 2: Agenda
Agenda 1 Executive Summary 2 1Q25 Financial & Operational Performance 3 Annual Achievements and Plan 4 Appendix
Slide 3: Executive Summary
Executive Summary
Slide 4: Executive Summary: 1Q 2025 Financial and Operational Highlights
Executive Summary 1Q 2025 Financial Highlights EGP 184 mn EGP 121 mn EGP 34.4 mn Revenues(1) Gross Profit EBITDA 210% YoY 232% YoY / 65.7% margin Vs. EGP -60.5 mn in 1Q24 / 18.7% margin EGP 22.4 mn EGP 25.9 mn EGP 37.9 mn Net Income Normalized Net Income(2) Adjusted EBITDA(2) Vs. EGP -78.1 mn in
Slide 5: 1Q25 Financial & Operational Performance
1Q25 | Financial & Operational Performance
Slide 6: 1Q25 Income Statement Highlights
1Q25 |Income Statement Highlights 1Q25 Highlights Revenues (1) Volume Sold Gross Profit (EGP mn) (mn units) (EGP mn/% margin) • Macro’s net revenues was up by a significant 210% YoY reaching EGP 184 million in 1Q25, the growth was primarily due to the total volumes sold more than doubling from last
Slide 7: Annual Achievements and Plan
Annual Achievements and Plan
Slide 8: 1Q25: Driving Growth Across Functions
1Q25: Driving Growth Across Functions Revenues | EGP mn Sales and Marketing April-March 2024/25 We successfully secured strong demand dynamics as reflected in a healthy in/out ratio surpassing both in and out sales targets. Additionally, we Sales growth concluded the Macroverse mega event which brou
Slide 9: 1Q25 Export Highlights
1Q25 | Export Highlights Total Export Revenues | EGP mn Export breakdown by country | 1Q25 32x Y-o-Y Exports were up significantly to reach EGP 5.5 million in 1Q25 from only EGP 0.17 million last year 15 14 contributing 3% to overall revenue. 33% During 1Q25 export markets included Saudi Arabia, O
Slide 10: 1Q25: Driving Growth Across Functions
1Q25: Driving Growth Across Functions Supply Chain Finance & IT Human Resources Plant and Admin - Rebuilding trust with suppliers, - Implementing three ticketing - Extensive salary benchmarking to - Completed several key following the resolution of past systems across the IT, SFE and improve our com
Slide 11: 1Q25: Driving Growth Across Functions
1Q25: Driving Growth Across Functions SF&E Investor R&D - As part of the new system, we - Successfully managed client - Team successfully found a solution implemented a GPS tracking relationships, while keeping for SKUs that faced shortages due feature has been introduced to investors and analyst up
Slide 12: Appendix
OY QO Appendix
Slide 13: 1Q25 Consolidated Income Statement
1Q25 | Consolidated Income Statement 1Q-2024 1Q-2025 % CHG Consolidated Income Statement | EGP Actual Actual Y-o-Y Sales Revenue(1) 59,536,121 184,387,191 209.7% COGS (23,054,632) (63,274,601) 174.5% Gross Profit 36,481,489 121,112,590 232.0% Gross profit margin 61.3% 65.7% 4.4 pps G&A Expenses (30,
Slide 14: 1Q25 Consolidated Balance Sheet
1Q25 | Consolidated Balance Sheet Consolidated Balance Sheet | EGP Dec-24 Mar-25 % CHG Y-o-Y Inventories 103,064,012 104,920,924 1.8% Trade and notes receivables 298,125,499 292,362,368 -1.9% Prepayments & other debit balances 50,746,961 53,728,120 5.9% Cash & cash equivalents 62,337,763 154,632,828
Slide 15: 1Q25 Consolidated Cash Flow Statement
1Q25 | Consolidated Cash Flow Statement % CHG % CHG Consolidated Cash Flow Statement | EGP 1Q24 1Q25 (Continued) 1Q24 1Q25 Y-o-Y Y-o-Y Cash flows from investing activities Cash flows from operating activities Payments to purchase of property, plant and Profit for the year before income tax (78,058,8
Macro Group Pharmaceutical S.a.e. — Q1 2025 Earnings Presentation on 6ix